Management of Ventricular Arrhythmias with Lidocaine

Indications and Usage

• The European Society of Cardiology recommends intravenous lidocaine for the treatment of recurrent sustained ventricular tachycardia or ventricular fibrillation not responding to beta-blockers or amiodarone, or in the presence of contraindications to amiodarone 1, 2
• Lidocaine is indicated for recurrent sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) not responding to first-line treatments, particularly when associated with acute myocardial ischemia or infarction 1, 3, 4
• The American College of Cardiology does not recommend lidocaine as prophylactic treatment in patients with uncomplicated acute myocardial infarction 5

Dosing and Administration

• The initial intravenous bolus of lidocaine is 1 mg/kg (not to exceed 100 mg) 6
• Additional bolus injections of 0.5 mg/kg can be administered every 8-10 minutes if necessary, to a maximum total of 4 mg/kg 6
• The maintenance infusion rate is 20-50 μg/kg/min (1.4-3.5 mg/min in a 70 kg patient) 6
• Patients requiring more than one bolus dose may need higher maintenance doses (up to 40-50 μg/kg/min) 6

Dosage Adjustments

• The American College of Cardiology recommends reducing the infusion rate in elderly patients due to increased risk of toxicity 5, 6
• In patients with heart failure, the dosage should be reduced as the half-life increases to >4 hours (compared to 1-2 hours in normal subjects) 6
• In patients with cardiogenic shock, significant reduction is needed as the half-life can exceed 20 hours 6
• In patients with hepatic dysfunction, the dosage should be reduced as lidocaine is primarily metabolized by the liver 5, 6

Monitoring and Precautions

• The European Heart Journal recommends monitoring blood pressure and cardiovascular status closely, especially in patients with heart failure or hypotension 3, 7
• The American College of Cardiology suggests considering measuring serum levels with prolonged or high infusion rates or if there are changes in neurologic condition 5
• Target therapeutic blood levels should be up to 5 μg/ml 6
• The American College of Cardiology advises against prophylactic use of lidocaine in uncomplicated acute myocardial infarction, as it has not shown mortality benefit and may increase risk of asystole 5, 6

Treatment Algorithm

• The European Society of Cardiology recommends a treatment algorithm starting with electrical cardioversion/defibrillation for hemodynamically unstable VT/VF, followed by beta-blockers, amiodarone, and finally lidocaine for recurrent VT/VF despite previous treatments 1, 2, 3